Mark S. Lepore, M.D. FAAAAI is Transpire Bio’s Chief Medical Officer, responsible for providing leadership in all areas related to pre-clinical and clinical development, drug safety, clinical operations, and medical affairs. As a member of the leadership team he is also responsible for developing the strategic direction of the company including the development of the company’s pipeline.
He began his career as a physician, board-certified in both General Pediatrics and Allergy, Clinical Immunology. After a decade in private practice, Dr. Lepore transitioned into drug development with roles at Teva and Lupin.
During his tenure with these companies he collaborated on the development of numerous inhaled therapeutics, including DPIs, MDIs, and nasal spray products. He’s helped shape discussions with regulators in the U.S., Europe, Japan, and elsewhere. He comes to Transpire Bio after stint with Aquestive Therapeutics as their Chief Medical Officer, advancing the world’s first sublingual treatment for anaphylaxis.